[The effects of the treatment for acute rejection with OKT3 monoclonal antibody treatment on the long-term results of cadaveric kidney transplantation].
Although the efficacy of OKT3 monoclonal antibody (OKT3) upon the steroid resistant rejection is well known, its beneficial effect on long-term result of kidney transplantation has not yet been well examined in Japan. A retrospective group study was performed to analyze the effect of OKT3 on the cadaver kidney allograft. Between September 1987 and October 1990, a total of 77 patients from four different hospitals were classified into 2 groups. Thirty-four patients from 2 hospitals were entered OKT3 therapy group and 43 patients from the other hospitals were entered steroid therapy group. Initial immunosuppression comprised low-dose cyclosporine (6 mg/kg), steroid and antilymphocyte globulin in both groups. In OKT3 therapy group, acute rejection episodes those were considered steroid resistant were observed in 7 patients. They were treated with OKT3 monoclonal antibody. Of the seven patients, six recovered normal renal function. The mild rejection in OKT3 therapy group was treated with high-dose steroid. Minimal follow-up was 2 years. The 2-year graft survival was 82.4% in OKT3 therapy group and 74.4% in steroid therapy group. Although the improvement on the 2 year graft survival with OKT3 treatment was 8%, the difference between two groups was not statistically significant.
Kinukawa
T
T
Department of Urology, Okazaki City Hospital.
Hattori
R
R
Ohshima
S
S
Matsuura
O
O
Takeuchi
N
N
Fujita
T
T
Nishiyama
N
N
Ono
Y
Y
Sahashi
M
M
Yamada
S
S
D000293:Adolescent; D000328:Adult; D002102:Cadaver; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies
D016853:Muromonab-CD3